labetalol has been researched along with Hypertrophy, Left Ventricular in 3 studies
Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.
labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.
2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.
Hypertrophy, Left Ventricular: Enlargement of the LEFT VENTRICLE of the heart. This increase in ventricular mass is attributed to sustained abnormal pressure or volume loads and is a contributor to cardiovascular morbidity and mortality.
| Excerpt | Relevance | Reference |
|---|---|---|
| "And we considered left ventricular hypertrophy as left ventricular mass index greater than 120 g/m2." | 5.28 | [Action of labetalol on norepinephrine myocardial content in left ventricular hypertrophy in hypertensive patients]. ( Boutelant, S; de Gaudemaris, R; Fagret, D; Mallion, JM; Schwebel, C; Siché, JP; Tremel, F, 1992) |
| " We treated 16-week-old rats having established LVH and myocardial fibrosis due to 8-week renovascular hypertension (RHT) with either 6 mg/kg/day zofenopril (ZOF), 30 mg/kg/day nifedipine (NIF) or 40 mg/kg/day labetalol (LAB) for 12 weeks." | 3.70 | Regression of myocardial fibrosis in hypertensive heart disease: diverse effects of various antihypertensive drugs. ( Brilla, CG, 2000) |
| "Carvedilol at a lower dose (7." | 1.30 | Carvedilol and lacidipine prevent cardiac hypertrophy and endothelin-1 gene overexpression after aortic banding. ( Donckier, J; Godfraind, T; Heyndrickx, GR; Kyselovic, J; Massart, PE; Wibo, M, 1999) |
| "And we considered left ventricular hypertrophy as left ventricular mass index greater than 120 g/m2." | 1.28 | [Action of labetalol on norepinephrine myocardial content in left ventricular hypertrophy in hypertensive patients]. ( Boutelant, S; de Gaudemaris, R; Fagret, D; Mallion, JM; Schwebel, C; Siché, JP; Tremel, F, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Massart, PE | 1 |
| Donckier, J | 1 |
| Kyselovic, J | 1 |
| Godfraind, T | 1 |
| Heyndrickx, GR | 1 |
| Wibo, M | 1 |
| Brilla, CG | 1 |
| Schwebel, C | 1 |
| Fagret, D | 1 |
| Tremel, F | 1 |
| Siché, JP | 1 |
| Boutelant, S | 1 |
| de Gaudemaris, R | 1 |
| Mallion, JM | 1 |
3 other studies available for labetalol and Hypertrophy, Left Ventricular
| Article | Year |
|---|---|
Carvedilol and lacidipine prevent cardiac hypertrophy and endothelin-1 gene overexpression after aortic banding.
Topics: Actins; Animals; Antihypertensive Agents; Aortic Diseases; Blood Pressure; Carbazoles; Carotid Arter | 1999 |
Regression of myocardial fibrosis in hypertensive heart disease: diverse effects of various antihypertensive drugs.
Topics: Animals; Antihypertensive Agents; Captopril; Collagen; Fibrosis; Hypertension, Renovascular; Hypertr | 2000 |
[Action of labetalol on norepinephrine myocardial content in left ventricular hypertrophy in hypertensive patients].
Topics: 3-Iodobenzylguanidine; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Iodine Radioisot | 1992 |